Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Gross Margin of 40.5% for Q1 2026, up 2710.0% year-over-year from 1.44% in Q1 2025, and down 19.5% quarter-over-quarter from 50.32% in Q4 2025.
Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Gross Margin for 4 consecutive years, with 40.5% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 2710.0% year-over-year to 40.5%; the TTM figure through Mar 2026 stood at 36.71% (up 413.0% YoY), while the FY2025 annual figure was 34.28%, down 889.0% from the prior year.
- Gross Margin fell to 40.5% in Q1 2026 per IOVA's latest filing, from 50.32% in the prior quarter.
- Across five years, Gross Margin topped out at 1211.41% in Q4 2023 and bottomed at 915.52% in Q1 2024.
- Historically, Gross Margin has averaged 87.01% across 4 years, with a median of 26.95% in 2025.
- Annual changes were most pronounced in 2024 — Gross Margin tumbled 116269 bps — and 2025, when it jumped 92892 bps.
- Iovance Biotherapeutics' Gross Margin stood at 1211.41% in 2023, then sank by 96 bps to 48.72% in 2024, then gained by 3 bps to 50.32% in 2025, then slipped by 20 bps to 40.5% in 2026.
- Business Quant data shows IOVA's Gross Margin at 40.5% in Q1 2026, 50.32% in Q4 2025, and 42.96% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 56.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.10% |
| Mar 31, 2026 | 40.50% |
| Dec 31, 2025 | 50.32% |
| Sep 30, 2025 | 42.96% |
| Jun 30, 2025 | 5.48% |
| Mar 31, 2025 | 13.40% |
| Dec 31, 2024 | 48.72% |
| Sep 30, 2024 | 46.17% |
| Jun 30, 2024 | -0.84% |
| Mar 31, 2024 | -915.52% |
| Dec 31, 2023 | 1,211.41% |
| Sep 30, 2023 | -825.37% |
| Jun 30, 2023 | -761.34% |